Regulation - Pricing, Cardio-vascular

Filter

Current filters:

PricingCardio-vascular

Popular Filters

1 to 25 of 28 results

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

Draft guidance from NICE recommends Bayer's Xarelto for PE and DVT

19-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) this morning (April 19)…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis

23-01-2013

In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse

25-09-2012

In final guidance issued this morning (September 26), UK drugs watchdog the National Institute for Health…

ActilyseBoehringer IngelheimCardio-vascularEuropePharmaceuticalPricingRegulation

UK NICE draft guidance backs Servier's Procoralan for chronic heart failure

06-08-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

Cardio-vascularEuropePharmaceuticalPricingProcoralanRegulationServier

UK NICE says final "yes" for Bayer's Xarelto to treat blood clots

24-07-2012

Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

"NICE" news for Bayer, as UK watchdog backs Xarelto for AF

23-05-2012

There was good news today (May 23) for German drug major Bayer (BAYN: DE), when the UK's drug watchdog,…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration

24-04-2012

The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

German IQWiG finds mixed added benefits for Eliquis

02-04-2012

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

NICE recommends NHS use of Pradaxa

15-03-2012

In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

UK NICE asks Bayer for Xarelto cost-effectiveness data

13-03-2012

UK health care price watchdog the National Institute for Health and Clinical Excellence (NICE), which…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Bayer’s Xarelto gets backing in Scotland

14-02-2012

German drug major Bayer’s (BAY: DE) oral anticoagulant Xarelto (rivaroxaban) has been accepted by…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

NICE publishes final technology appraisal guidance for four conditions

24-01-2012

The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

Brilique first drug to gain post-AMNOG decision in Germany

16-12-2011

The German health assessment body, the Federal Joint Committee (G-BA), has issued its final decision…

BriliqueCardio-vascularEuropePharmaceuticalPricingRegulation

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis

25-11-2011

In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

01-11-2011

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

UK’s NICE final guidance backs Takeda’s Mepact and AstraZeneca’s Brilique

26-10-2011

The UK’s National Institute for Health and Clinical Excellence (NICE) issued two final guidances…

AstraZenecaBrilintaBriliqueCardio-vascularEuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan

24-10-2011

Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Brilique/Brilinta…

AstraZenecaBrilintaBriliqueCardio-vascularDaiichi SankyoGastro-intestinalsNexiumPharmaceuticalPricingRegulation

1 to 25 of 28 results

Back to top